Hubert C. Chen
Chief Medical OfficerDr. Hubert C. Chen, M.D., MPH, is Chief Medical Officer of Attovia Therapeutics, Inc since March 2024. He was Chief R&D Officer of Cellular Longevity, Inc. from 2025 to March 2026. He served as Chief Development Officer of Cellular Longevity, Inc. until 2025. Dr. Chen is Chief Medical Officer of Viking Therapeutics, Inc. from June 2026. He served as Chief Medical Officer at ADARx Pharmaceuticals, Inc. from January 2022. He served as Senior Vice President of Clinical Development at Krystal Biotech, Inc. until 2024. He served as Chief Medical Officer at Metacrine, Inc. since August 2018 until December 31, 2021. Dr. Chen served as chief research and development officer at Loyal Animal Health, where he led the first-ever FDA-negotiated effectiveness and safety requirements for longevity therapeutics. He joined Forte Biosciences on June 07, 2022. He served as President and Chief Scientific Officer at Forte Biosciences, Inc. since June 07, 2022 until March 15, 2024. He was Medical and Scientific Advisor at Pfenex Inc. since February 2019 until April 2019. Dr. Chen is a Board certified endocrinologist with expertise in both clinical medicine and basic science research. His biotechnology career has spanned early to late-stage clinical development in multiple disease areas including hepatitis, fibrosis and inflammatory disease. Most recently, he served as Chief Medical & Scientific Officer at Pfenex Inc. from May 2017 until September 2, 2018 and now serves as its Advisor since September 1, 2018. He served as the Chief Medical Officer of Pfenex Inc. since November 2014 to May 2017. Dr. Chen served as Vice President of Clinical Development at Aileron Therapeutics, Inc. from July 2012 to October 2014. Dr. Chen served as Vice President of Translational Medicine at Regulus Therapeutics, LLC since September 2009 until June 2012 and was responsible for leading the translation of the important biological discoveries in the field of microRNA therapeutics into new medicines. From September 2006 to September 2009, Dr. Chen served as Director of Clinical Research and Senior Director of Corporate Development of Amylin Pharmaceuticals from 2006 to 2009. Prior to joining Regulus, Dr. Chen served as Senior Director of Clinical Research at Amylin Pharmaceuticals from 2006 to 2009. Previously, Dr. Chen led the early development of drugs for type 2 diabetes and metabolic disorders as Associate Director of Medical Sciences at Amgen Inc. from March 2004 to September 2006. From 2001 to 2004, Dr. Chen served as a Staff Research Investigator, Staff Scientist and Research Scientist at the Gladstone Institute of Cardiovascular Disease. From 2002 to 2012, he was Assistant Clinical Professor of Medicine at University of California, San Francisco (UCSF) and was a Clinical Fellow at both UCSF and Harvard Medical School. He performed his Postdoctoral Research at Gladstone Institute of Cardiovascular Disease and his Medical Residency at Massachusetts General Hospital from 1995 to 1998 and specialized in endocrinology at the University of California, San Francisco. Dr. Chen received an M.D. degree from Stanford University and a B.A.S. in Political Sciences and Biological Sciences from Stanford University in 1991 and M.P.H. from Harvard University.
Positions
- Company NameAttovia Therapeutics, Inc.Stock CodeATTOPositionChief Medical OfficerColleagues
- TFTao FuCEO, President & Director
- JNJames Newman TopperIndependent Chairman of the Board
- PVPetter VeibyChief Scientific Officer
- SCSteven ChanChief Financial Officer
- HZHangjun ZhanChief Technology Officer
- MHMitchell H. GoldIndependent Director
- AJAngie J. YouIndependent Director
- JWJohn W. SmitherIndependent Director
